Where health tech
meets real change.

Informal Thursday bar with Sundhedsdatastyrelsen

Health data access remains one of the most persistent bottlenecks in Danish health tech – shaped by processing times, complex pathways, and limited visibility into what’s even available. Digital Health Denmark, the new national body pulling these capabilities together, is just now taking shape.

Why attend
This is your chance to put questions directly to the person overseeing the system from the inside. Jesper Juel-Helwig, Deputy Director at Digital Health Denmark, opens the floor – no slides, no script. What data exists, how it can be accessed, why processes have taken this long, and what’s changing.

Who it’s for
Founders and leadership at health tech startups working with – or wanting to work with – Danish health data, tired of guessing their way through the system.

Format
An informal Thursday afternoon bar for members and ecosystem partners, centred on an open Ask Me Anything with Jesper. Bring your honest challenges, your curiosity, and your appetite for conversation.

Healthcare Catalyst: Region of Eastern Denmark

Getting time with a hospital’s innovation lead usually takes months of cold outreach and a fair amount of luck. This afternoon in central Copenhagen, Copenhagen Municipality, Region Zealand, Bispebjerg Hospital, North Zealand Hospital, and Rigshospitalet are all in the room, sharing their priorities directly.

Why attend
Providers share their strategic approach to innovation, current priorities, and where past partnerships have worked, then take your questions directly in ask-me-anything breakouts. It’s a first-hand look at each other’s priorities, needs, and collaboration potential – not a one-way pitch. If your solution fits a stated need, apply for a pre-matched 1:1 with real potential for a pilot or partnership.

Who it’s for
Health tech companies looking to build relationships with Region of Eastern Denmark’s hospitals and municipalities – especially if your solution fits a need they’ve named.

Format
A two-part afternoon: a joint session open to all members, no application needed, where providers share their priorities, followed by ask-me-anything breakouts with each one and networking.
A curated round of pre-matched 1:1s follows for companies whose solution fits a stated need – providers share their priorities with us upfront, and we do the matching. Applications for a 1:1 close 5 October.

How to join
Register below to join the open programme.
Complete the brief application when registering to be considered for a 1:1 conversation.

A hands-on workshop with Catalyze

Non-dilutive funding can accelerate growth for health and life sciences companies — but figuring out which of the European and Danish programmes actually fits, and what it takes to be a competitive applicant, is its own puzzle.

Why attend
By the end, you’ll know which programmes — Eureka Eurostars, the EIC tracks, the EUopStart voucher, Denmark’s Grand Solutions — actually fit your company, what evaluators look for and the pitfalls that sink applications, and the practical next steps for a realistic funding roadmap.

Who it’s for
Health tech companies looking for funding or grants, whether you’ve applied many times before, or this is your first.

Format
Interactive throughout, with live quizzes, polls, and Q&A (and possibly a prize on the line). Afterwards, book an optional 1:1 with the Catalyze team to talk through your own eligibility and funding strategy.

Market access strategy, pricing logic, and reimbursement positioning have moved from the back office to the boardroom. Whether you’re a seed-stage health tech defining your first evidence roadmap or a late-stage company preparing for partnership or exit, how you think about reimbursement pathways, value-based pricing, and payer narratives is no longer a regulatory checkbox – it’s a core determinant of company valuation, scalability, and investor confidence.

This workshop brings together founders, business development leaders, and market access professionals to explore a fundamental shift in how pricing and reimbursement should be aligned with how investors evaluate ventures. Early reimbursement thinking, evidence strategy, and pricing logic are now read as signals of commercial maturity and risk management – long before a product reaches its first payer negotiation.

Equally, a credible pricing strategy – one that aligns clinical evidence, health economic models, and willingness-to-pay across payer segments – is increasingly scrutinised in due diligence and partnership discussions.

We’ll examine how reimbursement architecture, pricing narrative, and market access strategy collectively shape commercialisation and funding decisions, influence partnership terms, and define exit potential – and what it takes to speak this language fluently at every stage of your company’s growth.

Who it’s for
Founders, BD leaders, and market access professionals in health tech and MedTech companies – from seed stage to late stage.